Exploration of catalytic properties of CYP2D6 and CYP3A4 through metabolic studies of levorphanol and levallorphan.

CYP2D6 and CYP3A4, two members of the cytochrome P450 superfamily of monooxygenases, mediate the biotransformation of a variety of xenobiotics. The two enzymes differ in substrate specificity and size and characteristics of the active site cavity. The aim of this study was to determine whether the catalytic properties of these isoforms, reflected by the differences observed from crystal structures and homology models, could be confirmed with experimental data. Detailed metabolite identification, reversible inhibition, and time-dependent inhibition were examined for levorphanol and levallorphan with CYP2D6 and CYP3A4. The studies were designed to provide a comparison of the orientations of substrates, the catalytic sites of the two enzymes, and the subsequent outcomes on metabolism and inhibition. The metabolite identification revealed that CYP3A4 catalyzed the formation of a variety of metabolites as a result of presenting different parts of the substrates to the heme. CYP2D6 was a poorer catalyst that led to a more limited number of metabolites that were interpreted in terms to two orientations of the substrates. The inhibition studies showed evidence for strong reversible inhibition of CYP2D6 but not for CYP3A4. Levallorphan acted as a time-dependent inhibitor on CYP3A4, indicating a productive binding mode with this enzyme not observed with CYP2D6 that presumably resulted from close interactions of the N-allyl moiety oriented toward the heme. All the results are in agreement with the large and flexible active site of CYP3A4 and the more restricted active site of CYP2D6.

Modified liquid junction interface for nonaqueous capillary electrophoresis-mass spectrometry.

Electrospray ionization (ESI) is the most widely used ionization method in on-line coupling of capillary electrophoresis-mass spectrometry (CE-MS). The conventional coaxial sheath flow electrospray interface is currently being replaced by the more sensitive nanoelectrospray technique. The usual limitation of nanoelectrospray CE-MS interface has been its short lifetime caused by deterioration of the metal coating on the CE capillary terminus. This article describes an easy way to construct a more durable and sensitive nanospray interface for nonaqueous CE-MS. In this approach a very thin glass spray capillary (ca. 30 microm outer diameter) is partly inserted inside the CE capillary, the junction being surrounded by the electrolyte medium, which is in contact with the platinum electrode. The interface was tested with five pharmaceuticals: methadone, pentazocine, levorphanol, dihydrocodeine, and morphine. Detection limits ranged from 12 to 540 fmol. Separation efficiency and reproducibility were also studied. The CE current was found to be stable and the migration times were highly reproducible. All the CE separations were carried out in a nonaqueous background electrolyte solution.

Effect of electrolyte and solvent composition on capillary electrophoretic separation of some pharmaceuticals in non-aqueous media.

Non-aqueous capillary electrophoresis was used to study the separation selectivity of positively charged drug substances and negatively charged diuretics. Study was made of the effects of organic solvent composition and the background electrolyte on the separation. The separation selectivity could be altered considerably by varying the methanol/acetonitrile composition. In addition, the migration order and the resolution of the pharmaceuticals could be altered merely by changing the electrolyte cation or the anion. The electrolytes tested were alkali metal acetates, ammonium acetate, ammonium chloride and ammonium bromide. As with aqueous background electrolyte solutions, the electroosmotic flow was decreased with increasing size of the alkali metal cation of the electrolyte in methanol/acetonitrile 50:50 (v/v).

Effects of nitrous oxide and halothane on mu and kappa opioid receptors in guinea-pig brain.

The effects of two general anesthetics, nitrous oxide and halothane, and oxygen on mu and kappa opioid receptor subtypes from guinea-pig brain were investigated. mu receptor binding was defined using [3H]dihydromorphine as the ligand. Nitrous oxide (100%) and halothane (2%) decreased the [3H]dihydromorphine binding affinity (Kdair = 0.87 nM, KdN2O = 1.45 nM, Kdhalothane = 2.30 nM) without affecting the density of binding sites. A decrease in the [3H]dihydromorphine binding affinity without influence on the density of binding sites was also observed in the presence of 100% oxygen (KdO2 = 1.40 nM). kappa receptor binding was defined using [3H](-)ethylketocyclazocine as the ligand, in the presence of 100 nM D-ala2-D-leu5-enkephalin and 30 nM morphine. While 100% nitrous oxide caused a slight decrease in [3H](-)ethylketocyclazocine binding affinity (Kdair = 0.24 nM, KdN2O = 0.31 nM) and a substantial decrease in the density of binding sites (Bmaxair = 115 fmol/mg protein, BmaxN2O = 84 fmol/mg protein), halothane dramatically affected both the affinity (Kdhalothane = 0.70 nM) and density (Bmaxhalothane = 38 fmol/mg protein). Oxygen (100%) reduced [3H]dihydromorphine binding affinity. Differential effects of two anesthetics on the same receptor or distinct actions of the same anesthetic on different receptors could indicate the presence of specific targets for anesthetics at the membrane level. Conversely, effects of volatile anesthetics on opioid receptors could reflect a non-specific perturbation of the lipidic and proteinaceous components of the membranes.

Levorphanol: a simplified radioimmunoassay for clinical use.

A recently reported radioimmunoassay (RIA) procedure (Res. Comm. Chem. Pathol. Pharmacol 29, 535, 1980) developed for the quantitation of the narcotic analgesic, levorphanol, in dog plasma has been simplified for clinical use using the original antiserum to an albumin conjugate of (-)-3-hydroxy-N-carboxymethylmorphinan. Due to the absence of and/or insignificant concentrations of the cross-reactive metabolite, nor-levorphanol, in human plasma, the new simplified procedure allows for the specific quantitation of levorphanol directly in clinical plasma samples, thereby circumventing the extraction and chromatographic steps of the original procedure. The direct procedure has a limit of sensitivity of 1 ng/ml of levorphanol using a 20 microliter sample of plasma and is ideally suited for the routine determination of steady state plasma concentrations of levorphanol in patients receiving various therapeutic doses of the drug. In two subjects studied the apparent half-lives of elimination of levorphanol from plasma were 10 and 16 hr. The characteristics and use of another antiserum to levorphanol, obtained by immunization of rabbits with an albumin conjugate of (-)-3-O-carboxymethyl-N-methylmorphinan, is discussed.

Stereospecific and nonspecific interactions of the morphine congener levorphanol in subcellular fractions of mouse brain.

A METHOD IS DESCRIBED FOR ANALYZING THE ASSOCIATION OF THE OPIATE NARCOTIC LEVORPHANOL WITH BRAIN TISSUE INTO THREE COMPONENTS: nonsaturable, saturable nonspecific, and saturable stereospecific. The method may be of general applicability for the study of the interaction of drugs with body tissues. In mouse brain the stereospecific binding of levorphanol represents only 2% of the total association of drug with tissue, and it was found only in certain membrane fractions. The material responsible for the stereospecific binding might be the opiate receptor.